15-Year safety check for experimental CAR t therapy begins
NCT ID NCT07403188
First seen Feb 13, 2026 · Last updated May 14, 2026 · Updated 14 times
Summary
This study tracks 70 people who have already received an infusion of KYV-101, a CAR T cell therapy, for autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis. The goal is to watch for delayed side effects, new cancers, or other health problems over up to 15 years. No new treatment is given—this is purely a safety monitoring study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Colorado, Denver
RECRUITINGDenver, Colorado, 80045, United States
Contact
Conditions
Explore the condition pages connected to this study.